| Market Cap | 124.96M | P/E | - | EPS this Y | 24.00% | Ern Qtrly Grth | - |
| Income | -121.64M | Forward P/E | -1.25 | EPS next Y | 20.50% | 50D Avg Chg | -9.00% |
| Sales | 591.86k | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -61.00% |
| Dividend | N/A | Price/Book | 0.63 | EPS next 5Y | 41.50% | 52W High Chg | -83.00% |
| Recommedations | 2.20 | Quick Ratio | 4.25 | Shares Outstanding | 25.96M | 52W Low Chg | 25.00% |
| Insider Own | 0.85% | ROA | -39.91% | Shares Float | 23.48M | Beta | 0.83 |
| Inst Own | 31.26% | ROE | -91.42% | Shares Shorted/Prior | 3.05M/2.92M | Price | 0.48 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 9,115,987 | Target Price | 16.75 |
| Oper. Margin | -32,945.87% | Earnings Date | Nov 7 | Volume | 2,949,979 | Change | -4.38% |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
| Oppenheimer | Outperform | Aug 12, 24 |
| RBC Capital | Sector Perform | Aug 9, 24 |
| HC Wainwright & Co. | Neutral | Jul 15, 24 |
| Stephens & Co. | Overweight | May 14, 24 |
| Oppenheimer | Outperform | Mar 8, 24 |
| RBC Capital | Sector Perform | Mar 7, 24 |
| Oppenheimer | Outperform | Jan 25, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Weiner David B. | Director Director | Mar 11 | Sell | 1.15 | 5,833 | 6,708 | 910,124 | 03/13/23 |
| Weiner David B. | Director Director | Feb 26 | Sell | 1.28 | 11,668 | 14,935 | 904,291 | 02/28/23 |
| Weiner David B. | Director Director | Aug 11 | Option | 2.16 | 11,875 | 25,650 | 904,500 | 08/11/22 |
| Weiner David B. | Director Director | Aug 11 | Sell | 2.66 | 11,875 | 31,588 | 892,625 | 08/11/22 |
| BENITO SIMON X | Director Director | Mar 16 | Option | 2.2 | 2,000 | 4,400 | 59,305 | 03/17/22 |
| BENITO SIMON X | Director Director | Mar 16 | Sell | 3.16 | 2,000 | 6,320 | 57,305 | 03/17/22 |
| Weiner David B. | Director Director | Mar 08 | Sell | 3.33 | 4,083 | 13,596 | 876,041 | 03/09/22 |
| Weiner David B. | Director Director | Apr 21 | Option | 2.4 | 22,500 | 54,000 | 877,719 | 04/21/21 |
| BENITO SIMON X | Director Director | Apr 16 | Option | 3.56 | 2,000 | 7,120 | 53,650 | 04/16/21 |
| Weiner David B. | Director Director | Mar 09 | Sell | 9.39 | 7,000 | 65,730 | 843,552 | 03/09/21 |
| Kim Jong Joseph | Chief Executive Offi.. Chief Executive Officer | Feb 03 | Option | 4.56 | 62,500 | 285,000 | 1,140,813 | 02/03/21 |
| Kim Jong Joseph | Chief Executive Offi.. Chief Executive Officer | Feb 03 | Sell | 14.62 | 162,500 | 2,375,750 | 1,078,313 | 02/03/21 |
| Shea Jacqueline Elizabeth | Chief Operating Offi.. Chief Operating Officer | Feb 03 | Option | 3.62 | 22,376 | 81,001 | 66,871 | 02/03/21 |
| Shea Jacqueline Elizabeth | Chief Operating Offi.. Chief Operating Officer | Feb 03 | Sell | 15.03 | 28,336 | 425,890 | 38,535 | 02/03/21 |
| KIES PETER | CFO CFO | Jan 15 | Option | 4.56 | 30,000 | 136,800 | 149,290 | 01/15/21 |
| KIES PETER | CFO CFO | Jan 15 | Sell | 10.02 | 30,000 | 300,600 | 119,290 | 01/15/21 |
| KIES PETER | CFO CFO | Dec 17 | Option | 2.28 | 20,000 | 45,600 | 139,290 | 12/17/20 |
| KIES PETER | CFO CFO | Dec 17 | Sell | 10.69 | 20,000 | 213,800 | 119,290 | 12/17/20 |
| Weiner David B. | Director Director | Dec 17 | Option | 4.56 | 17,500 | 79,800 | 844,719 | 12/17/20 |
| Weiner David B. | Director Director | Dec 17 | Sell | 10.71 | 17,500 | 187,425 | 827,219 | 12/17/20 |